

Abstract 885: Anti-CSPG4 CAR.CIK lymphocytes are effective against advanced sarcomas in 3D spheroid and xenograft models **FREE**

Chiara Donini; Valeria Leuci; Ramona Rotolo; Giovanni Grignani; Giulia Mesiano; Erika Fiorino; Loretta Gammaitoni; Lorenzo D'Ambrosio; Soldano Ferrone; Massimo Aglietta; Gianpietro Dotti; Dario Sangiolo



+ Author & Article Information

Cancer Res (2020) 80 (16_Supplement): 885.

<https://doi.org/10.1158/1538-7445.AM2020-885>

Split-Screen

Share ▾

Tools ▾

Versions ▾

Abstract

Purpose of this study is to explore, *in vivo* and within tridimensional (3D) models, a novel CAR-based adoptive immunotherapy against incurable soft tissue sarcomas (STS). The strategy focuses on Cytokine-Induced Killer (CIK) lymphocytes redirected against the Chondroitin Sulfate Proteoglycan 4 (CSPG4) target, associated with tumorigenesis, tumor aggressiveness and negative clinical outcome. CIK are *ex vivo* expanded T-NK lymphocytes endowed with intrinsic HLA-independent antitumor activity.

Experimental procedures. The experimental platform is based on patient-derived CAR.CIK and multiple histotypes of STS. CAR.CIK were generated by transduction of PBMC with a retroviral vector encoding for a 2nd generation anti-CSPG4 CAR with 4-1BB costimulation. 3D *in vitro* essays were based on STS spheroids generated in ultralow attachment conditions. *In vivo* experiments included 3 different STS xenograft models (fibrosarcoma, leiomyosarcoma, UPS).

Results. CAR.CIK were efficiently generated by STS patients (n=5). Mean expression of anti-CSPG4 was 44%±6.2, rates of *ex vivo* expansion (29 fold, range 27-348) and phenotype (CD8: 65%±4; CD56: 38%±6, NKG2D: 66%±7) were comparable with unmodified controls (NTD.CIK.). The CSPG4 target resulted expressed in 16/17 STS (leiomyosarcoma n=2, fibrosarcoma n=1, UPS n=6, GIST n=5, liposarcoma n=3), with variable membrane density per cell (300±47). CAR.CIK efficiently killed all STS *in vitro* regardless of their histotype. Mean STS-specific killing by CAR.CIK was significantly higher compared with NTD.CIK (E:T 1:1: 71% vs 34%, p <0.0001). Within 2 different STS 3D-spheroid models, CAR.CIK showed higher penetration ability through Matrigel matrix (n=5 p≤0.05), tumor recruitment, infiltration (n=8, p≤0.01) and killing (n=3, p<0.0001) compared with NTD.CIK. Anti-STS activity by CAR.CIK appeared proportionally dependent on CSPG4 density in STS targets. We set 3 different STS xenografts (fibrosarcoma,

leiomyosarcoma, UPS) in immunocompromised mice, differing for CSPG4 expression and density levels per cell. Treatment with CAR.CIK (autologous in 2/3 cases) determined a significant delay of tumor growth ($p < 0.0001$) compared with controls, demonstrating intense STS infiltration after treatment. A persistent antitumor response was observed up to 2 weeks after end of treatment. Also in vivo, we confirmed a positive correlation between the observed anti-STS activity of CAR.CIK and target CSPG4 expression/density on tumor cells.

Conclusions. We report the intense activity of anti-CSPG4 CAR.CIK against multiple histotypes of currently incurable STS. CIK lymphocytes, considering their intrinsic antitumor activity, may be a favorable platform for the translation of CAR-based strategies against solid tumors. Our findings support anti-CSPG4 CAR.CIK as a promising therapeutic strategy warranting clinical exploration in the challenging field of advanced STS.

Citation Format: Chiara Donini, Valeria Leuci, Ramona Rotolo, Giovanni Grignani, Giulia Mesiano, Erika Fiorino, Loretta Gammaitoni, Lorenzo D'Ambrosio, Soldano Ferrone, Massimo Aglietta, Gianpietro Dotti, Dario Sangiolo. Anti-CSPG4 CAR.CIK lymphocytes are effective against advanced sarcomas in 3D spheroid and xenograft models [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 885.

©2020 American Association for Cancer Research.

Advertisement

[View Metrics](#)

[Skip to Main Content](#)

Citing Articles Via

[Google Scholar](#)

 **Email Alerts**

[Article Activity Alert](#)

[eTOC Alert](#)

Advertisement

[Issues](#)

[Online First](#)

[Collections](#)

[News](#)

[Twitter](#)

Online ISSN 1538-7445 **Print ISSN** 0008-5472

AACR Journals

[Blood Cancer Discovery](#)

[Cancer Discovery](#)

[Cancer Epidemiology, Biomarkers, & Prevention](#)

[Cancer Immunology Research](#)

[Cancer Prevention Research](#)

[Cancer Research](#)

[Cancer Research Communications](#)

[Clinical Cancer Research](#)

[Molecular Cancer Research](#)

[Molecular Cancer Therapeutics](#)

[Skip to Main Content](#)

[Info for Advertisers](#)

[Info for Advertisers](#)

[Info for Librarians](#)

[Privacy Policy](#)



[in](#)

[f](#)



Copyright © 2022 by the American Association for Cancer Research.